Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Getting Married
- Sorry Guardian - You Get An F minus for linguistics
- The Three Cubes Problem
- Debunked: World To End After Two Snowy Days In Salento, Puglia, Southern Italy, Tears On Macedonia Icon
- Eugene Cernan, Hometown Astronaut of Bellwood Illinois dead at 82.
- Anomaly! At 35% Discount For Ten More Days
- Lisa Long Leg: Vongehr’s Rational Free Speech Trump Cross For The Alt Right Revolution Of Love
- "I don't know why my comment's formatting was lost in the transmission, so that it is now one big..."
- "“If you don't use probabilities then how else do you do it? At any rate that's not a criticism..."
- "Tomasso, Congratulations, may you enjoy a long and happy life together with Kalliopi! Best regards..."
- "Found another one : http://www.dailystar.co.uk/news/latest-news/545975/end-of-the-world-Gods-vengeance..."
- "Thanks :). Actually there are so many fake doomsday red top tabloid stories that I tend to wait..."
- If You Think Fentanyl Is Bad...
- Let's Learn a Lesson from Theranos
- Guardians of Truth: Mike Huckabee Lauds Us, We Ruin Things for RFK Jr., And More Media Links
- Massachusetts Becomes the 20th State Where Naturopaths Can Hurt You
- Turmeric- The New Superfood. Oops. Superfad.
- CRRREST Education: How to Fix America's Illiteracy Problem